Form 4: Gyre Therapeutics COO Trades Shares

Gyre Therapeutics Chief Operating Officer, Ye Weiguo, reported transactions involving the acquisition and disposition of company stock, including the exercise of stock options.

Summary

• Ye Weiguo, Chief Operating Officer of Gyre Therapeutics, Inc., engaged in several transactions on June 9th and June 10th, 2026.
• On June 9th, 2026, 14,500 shares of common stock were acquired at a price of $0.75 per share, and 14,500 shares were disposed of at a weighted average price of $6.14.
• On June 10th, 2026, an additional 6,418 shares of common stock were acquired at $0.75 per share, and 6,418 shares were disposed of at a weighted average price of $6.21.
• The filing also details the exercise of stock options, with 14,500 options exercised on June 9th and 6,418 options exercised on June 10th, both at an exercise price of $0.75 per share, with an expiration date of October 31st, 2030.
• Following these transactions, Ye Weiguo beneficially owns 700,000 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports routine insider transactions involving stock option exercises and sales, without providing new strategic or financial information.

Positives

• The acquisition of shares at a lower price ($0.75) alongside dispositions at higher market prices ($6.14 and $6.21) suggests a strategic exercise of options and potential profit-taking.
• The COO continues to hold a significant number of shares (700,000) directly, indicating continued confidence in the company.

Negatives

• A substantial number of shares were disposed of, which could be interpreted as a reduction in direct holdings by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported transactions by Gyre Therapeutics' COO are typical for executives managing stock options and potentially diversifying holdings, but the scale of dispositions warrants attention.

Stakeholder Impact

• Shareholders may observe the disposition of shares by the COO, which could influence short-term trading sentiment, though the continued large beneficial ownership mitigates significant concern.

Key Dates

Keywords

Gyre Therapeutics, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Ye Weiguo, SEC Filing, Common Stock